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PSA progression: 11.3 months). All but one patient remain 
alive (1 year survival: 88.9%). No grade 3+ acute 
toxicities were observed and no grade 3+ late toxicities 
have been reported to date. Vessels were the OAR most 
often within the reRT PTV, but were not dose limiting. 
Small bowel, colon and sacral plexus were within the PTV 
in 7, 5 and 7 cases respectively and were potentially dose 
limiting. Cumulatively, allowing for potential positional 
change between RT courses, 'worst case' calculated doses 
to small bowel, colon and sacral plexus were up to 111, 
107 and 123Gy (EDQ2, α/β=3Gy), respectively (Table 2). 
 
 
 
Conclusion  
SABR reRT appears well tolerated and effective in 
controlling oligometastatic pelvic disease. Cumulative 
doses and positional changes in OARs between courses 
should be considered. SABR reRT requires further 
evaluation in prospective trials to guide future delivery. 
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Purpose or Objective  
Stereotactic body radiation therapy (SBRT) for painful 
spinal metastases has the potential to improve and 
extend pain relief, but prospective data on pain response 
are lacking. This prospective phase II trial addressed the 
question of overall (complete and partial) pain response 
after hypo-fractionated SBRT for painful, mechanically 
stable, previously un-irradiated spinal metastases?   
Material and Methods  
From 2012 to 2015, 54 patients were treated and 
analyzed in a prospective, multicenter, non-randomized, 
single arm phase 2 study (NCT01594892). Inclusion 
criteria were ≤2 distinct, non-contiguous, painful, 
mechanically stable, un-irradiated spinal metastases from 
a solid tumor, Karnofsky performance status ≥60. Patients 
with long (Mizumoto score ≤4) or intermediate (Mizumoto 
score 5-9) overall survival expectancy were treated with 
hypo-fractionated SBRT of 48.5 Gy in 10 fractions or 35 
Gy in 5 fractions, respectively. The primary outcome was 
overall (complete and partial) pain response measured 
with the International Consensus Guidelines at 3 months 
after SBRT; the secondary outcome was local control, 
survival, toxicity and quality-of-life measured with the 
Euro-quality-of-life Five Dimensions Questionnaire (EQ-
5D-5L). 
Results  
Of 54 patients (30 [56%] male; median [range] age 64 [25-
84] years; 60 lesions) 30 (56%) patients were treated with 
10-fraction SBRT and 24 (44%) with 5-fraction SBRT. Pain 
response at 3-months was evaluated in 42 patients (47 
lesions). Overall pain response was observed in 41 lesions 
(87%) and pain response remained stable for at least 12 
months. Mean (standard deviation) maximum pain scores 
on Visual Analogue Score significantly improved from 
baseline 6.1 (2.5)  to 2.0 (2.3) at 3 months post-
treatment (P<.001). EQ-5D-5L quality-of-life dimensions 
(self-reported mobility, usual activities and 
pain/depression) significantly improved from baseline to 
3 months post-treatment. After a median follow-up of 12 
months, the 12-month overall survival and local control 
rates were 61.4% (95% CI, 48-74.8%) and 85.9% (95% CI, 
76.7-95 %), respectively. Grade 3 toxicity was limited to 
acute pain in 1 patient (2%). No patient experienced 
radiation-induced myelopathy. Six (11%) and 8 (15%) 
patients developed progressive or new vertebral 
compression fractures (VCF), respectively, but 
stabilization (n=1) and decompression (n=1) surgery was 
only required in two patients.   
Conclusion  
SBRT for painful vertebral metastases achieved rapid, 
deep and long-term overall pain response, high local 
metastasis control and improved quality-of-life a nd may 
become a primary treatment in selected patients with 
longer survival expectancy.  
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Purpose or Objective  
Surgery is the standard of care for early stage lung 
cancer. Stereotactic ablative radiotherapy (SABR) is a low 
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morbidity option in a population whose physiological 
reserve is often limited. The role of SABR is, however, 
not yet well defined. Randomised studies have failed to 
recruit and retrospective analyses are confounded by 
significant co-morbidity and frailty. This study aims to 
compare the cancer-specific survival outcomes for 
varying treatment strategies in a cohort of patients 
treated for presumed early stage NSCLC acknowledging 
the competing risk of death due to co-morbidity. 
Material and Methods  
All patients treated for presumed stage I lung cancer 
between January 2008 and May 2013 in a large UK centre 
were identified retrospectively. Treatment received, 
baseline characteristics, survival, recurrence and cause 
of death information were collected. Multi-variable Fine 
and Gray competing risks models adjusted for stage, age, 
performance status, sex and treatment were used to 
assess cancer-specific survival, whilst acknowledging 
deaths due to other causes. Cox proportional hazards 
models were built for comparison. Stacked cumulative 
incidence plots provide a visual representation of cause-
specific mortality. 
Results  
The study cohort consisted of 468 individuals. 316 (67.5%) 
underwent surgical resection, 99 (21.2%) received SABR 
and 53 (11.3 %) conventionally fractionated radiotherapy. 
SABR was associated with inferior overall survival in Cox 
proportional hazards multi-variable models compared to 
surgery despite adjustment for baseline co-variables 
(SABR HR 1.840, 95% CI 1.317-2.570, p< 0.001). On 
competing risks analysis SABR and surgery were 
associated with equivalent cancer-specific survival (Sub-
distribution hazard for SABR 1.030, 95%CI 0.585-1.814, 
p=0.919). This finding was mirrored on multi-variable Cox 
proportional hazards modelling of cancer-specific survival 
(SABR HR 1.271, 95% CI 0.744-2.170, p=0.380). The 
hazard ratio for SABR increased when outcomes beyond 
90 days post treatment were considered (SABR HR on Cox 
modelling 1.607, 95% CI 0.931-2.772, p=0.088) although 
this was not significant. Figures 1 and 2 show the 
cumulative incidence of death due to varying causes 
following surgery and SABR respectively. 
 
Fig.1 
 
 
Fig.2 
 
 
Conclusion  
In this cohort, SABR was associated with equivalent 
cancer-specific survival to surgery on both Fine and Gray 
and Cox modelling. The possible time-dependence of this 
result is of interest and if replicated on Fine and Gray 
modelling in a larger cohort may suggest that case 
selection is critical; early treatment related mortality 
following surgery cancelling out any potential benefits in 
those at even moderate risk of surgical mortality. Further 
work is required. Whilst randomised data would be 
optimal a pragmatic approach, increasing the size of the 
investigated cohort and considering survival, quality of 
life and cost-effectiveness outcomes would provide 
valuable information to support clinical decision making. 
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Abstract text  
The expectations and rights of ‘consumers’ (patients) 
within healthcare systems and services are being more 
explicitly articulated as time goes on. The patient 
experience and satisfaction with their care are 
recognised as significant indicators of service quality, and 
rightly so.  Similarly, explicit focus on patient-centred 
care, patient safety and the inclusion of patients within 
healthcare innovation is highlighted within modern health 
professional training programs and quality improvement 
programs. Further, in the area of research the value of 
including patient reported outcome measures (PROMs) in 
clinical trials has gained increasing focus over recent 
years and nowhere is this more evident than in the case 
of cancer studies. It is well recognised that trade-offs 
between ‘hard’ cancer endpoints such as survival, and 
quality-of-life or symptoms often varies between 
individuals. Patient preferences in decision-making are 
often personal and a movement away from a paternalistic 
approach in clinical care to shared decision-making is 
becoming the norm within radiation oncology. In all these 
ways, our patients are moving more towards having a 
partnership role as key members of the decision-making, 
management, quality improvement and research teams 
within which we work. In addition, they have a powerful 
voice in advocating for our specialty and for cancer 
patients’ support and information needs. This talk will 
explore the concept of patients as our teachers and 
inspiration in relation to what really matters to them and 
the research questions we need to ask. Alliances between 
radiation oncology professionals and patients represent a 
potentially under-tapped, yet very powerful, advocacy 
and research resource. 
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Abstract text  
Nowadays, the need to involve cancer patients in 
treatment decision-making and to assess patients´ values 
in preference-sensitive decision situations becomes more 
and more recognized, especially when the expected 
benefit is marginal, a treatment carries significant risks 
or side effects, or decision makers disagree in their 
valuation of treatment outcomes. Involving cancer 
